Kevin P. Jansen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Kevin P. Jansen has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- Dominic L. Palazzolo
DeBusk College of Osteopathic Medicine, Lincoln Memorial University, Harrogate, TN 37752, USA
1 shared publication
Latest Publications
- 8 August 2008
- Published by Springer Nature in Biological Trace Element Research
- Vol. 126 (1-3) , 49-55
The Minimal Arsenic Concentration Required to Inhibit the Activity of Thyroid Peroxidase Activity In Vitro
Arsenical compounds are known to interfere with normal thyroid function. Therefore, we designed an experiment to determine the minimal concentration of arsenic trioxide (As2O3) required to inhibit thyroid peroxidase (TPO) activity in vitro. The activity of commercially prepared human TPO was assayed spectrophotometrically in the absence (control) or presence of arsenic (0.1, 1.0, 5.0, and 10 ppm) during a 10-min incubation period. The results of this study indicate a significant dose–response relationship with the highest concentration of arsenic producing the greatest amount of TPO inhibition. Compared to controls, 0.1 ppm arsenic had no effect on TPO activity. Incubation for 2 min in the presence of 1.0, 5.0, or 10 ppm arsenic inhibited TPO activity to 4%, 9%, and 9% of control, respectively. After 10 min incubation in the presence of 1.0 or 5.0 ppm arsenic, TPO activity returned to 92% and 54% of control, respectively, while the presence of 10 ppm arsenic further inhibited TPO activity to 1% of control. In summary, arsenic trioxide inhibits in vitro TPO activity in a dose-dependent manner, and the minimal dose required to inhibit this activity is between 0.1 and 1 ppm.
- 8 August 2008
- Published by Springer Nature in Biological Trace Element Research
- Vol. 126 (1-3) , 49-55
The Minimal Arsenic Concentration Required to Inhibit the Activity of Thyroid Peroxidase Activity In Vitro
Arsenical compounds are known to interfere with normal thyroid function. Therefore, we designed an experiment to determine the minimal concentration of arsenic trioxide (As2O3) required to inhibit thyroid peroxidase (TPO) activity in vitro. The activity of commercially prepared human TPO was assayed spectrophotometrically in the absence (control) or presence of arsenic (0.1, 1.0, 5.0, and 10 ppm) during a 10-min incubation period. The results of this study indicate a significant dose–response relationship with the highest concentration of arsenic producing the greatest amount of TPO inhibition. Compared to controls, 0.1 ppm arsenic had no effect on TPO activity. Incubation for 2 min in the presence of 1.0, 5.0, or 10 ppm arsenic inhibited TPO activity to 4%, 9%, and 9% of control, respectively. After 10 min incubation in the presence of 1.0 or 5.0 ppm arsenic, TPO activity returned to 92% and 54% of control, respectively, while the presence of 10 ppm arsenic further inhibited TPO activity to 1% of control. In summary, arsenic trioxide inhibits in vitro TPO activity in a dose-dependent manner, and the minimal dose required to inhibit this activity is between 0.1 and 1 ppm.